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Contrast-induced acute kidney injury (CI-AKI) is commonly defined as a decline in kidney function occurring in a narrow time
window after administration of iodinated contrast material. The incidence of AKI after contrast material administration greatly
depends on the specific definition and cutoff values used. Although self-limiting in most cases, postcontrast AKI carries a risk of
more permanent renal insufficiency, dialysis, and death. The risk of AKI from contrast material, in particular when administered
intravenously for contrast-enhanced CT, has been exaggerated by older, noncontrolled studies due to background fluctuations in
renal function.More recent evidence from controlled studies suggests that the risk is likely nonexistent in patients with normal renal
function, but there may be a risk in patients with renal insufficiency. However, even in this patient population, the risk of CI-AKI
is probably much smaller than traditionally assumed. Since volume expansion is the only preventive strategy with a convincing
evidence base, liberal hydration should be encouraged to further minimize the risk. The benefits of the diagnostic information
gained from contrast-enhanced examinations will still need to be balanced with the potential risk of CI-AKI for the individual
patient and clinical scenario.
1. Introduction
Soon after modern iodinated contrast agents had been
introduced, they have been causally linked to acute kidney
injury (AKI) [1, 2]. A large number of noncontrolled obser-
vational studies have since investigated the frequency of AKI
following intra-arterial and intravenous administration of
contrast material (CM) and the overwhelming majority of
studies found a significant risk [3]. Consequently, the risk
of contrast-induced acute kidney injury (CI-AKI) has been
widely accepted in medical literature and practice [4, 5].
Indeed, fear of CI-AKI is one of the most frequent reasons
why CM is withheld from patients undergoing computed
tomography (CT) and thus frequently compromises the
diagnostic information gained from CT [6].
This traditional concept has been challenged recently, in
particular for intravenous administration of contrastmaterial
[4]. This paradigm shift began when studies demonstrated a
high rate of fluctuation in kidney function in patients without
exposure to iodinated contrast material [7, 8], indicating that
the existing observational studies on CI-AKI without a non-
exposed control group are fundamentally flawed and likely
to greatly overestimate the incidence of CI-AKI. Since then,
a number of controlled studies have been performed exam-
ining the incidence of AKI in patients undergoing contrast-
enhanced CT compared to patients undergoing noncontrast
CT. A recent meta-analysis of 13 controlled studies found
a similar or lower rate of AKI following contrast-enhanced
CT compared to noncontrast CT indicating that CM is likely
not the causative agent in the majority of postcontrast AKI
cases [9]. It is, however, important to keep in mind that all of
these controlled studies had a nonrandomized study design,
whichmakes them vulnerable to selection bias, since patients
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perceived to be at risk for AKI are more likely to receive
noncontrast CT examinations [2].
In view of this recent controversy, this paper reviews
some fundamental aspects of the current concept of CI-
AKI including its definition, epidemiology, and outcome
and attempts to draw conclusions as to how the balance
between avoiding AKI and gaining the necessary diagnostic
information may need to be readjusted as a consequence of
the recently published new evidence.
2. Definition
CI-AKI is commonly defined as a rise in blood urea nitro-
gen (BUN), serum creatinine, or a decline in estimated
glomerular filtration rate (eGFR) occurring in a narrow
time window—typically 24–72 hours—after administration
of iodinated CM. In a recent meta-analysis of controlled
studies on intravenous CM, definitions of AKI based on
serum creatinine levels ranged from 0.3 to 0.5mg/dL for an
absolute increase and from 25 to 50% for a relative increase
[9]. An absolute increase of serum creatinine by ≥0.5mg/dL
from baseline is a simple and still widely used definition of
AKI [10]. Another commonly used definition is based on
the criteria originally proposed by Barrett and Parfrey which
considerCI-AKI to be present if an absolute increase in serum
creatinine levels by ≥0.5mg/dL or a relative increase in serum
creatinine by ≥25% from baseline is observed within 72 hours
after contrast exposure [11].
A more recent standardized definition of AKI was pro-
posed by the Acute Kidney Injury Network (AKIN) and
defines AKI if at least one of three conditions is met: (a) an
absolute increase in serum creatinine levels by ≥0.3mg/dL
from baseline, (b) a relative increase in serum creatinine
by ≥50% from baseline, or (c) a urine output reduced to
≤0.5mL/kg/hour for at least 6 hours [12–14]. This definition
is not designed for or specific to CI-AKI. However, the
American College of Radiology has recommended using
the AKIN criteria (occurring within 48 hours after the
administration of iodinated CM) to define contrast-induced
nephropathy in order to standardize the varying definitions
found in the literature [15, 16]. Since urine output is not
routinely measured in noncritically ill patients, the first two
of the 3 criteria listed above have been used to define AKI in
recent studies on CI-AKI with intravenous CM [15, 17].
The RIFLE classification is an alternative classification
system which defines different stages of acute kidney injury
(risk, injury, failure, loss, and end-stage renal disease) based
on changes in serum creatinine or eGFR and urine output [12,
18]. In this classification, kidney injury is defined as a >100%
increase in serum creatinine, a >50% decrease in eGFR, or
a urine output of less than 0.5mL/kg/h for 12 hours. This
classification has been applied to postcontrast AKI [19, 20]
but is not commonly used in this setting.
The incidence of AKI after contrast material adminis-
tration greatly depends on the specific definition and cutoff
values used to define AKI. For example, a prospective
observational study of patients receiving intravenous contrast
material for contrast-enhanced CT examined six different
definitions of CI-AKI based on repeat serum creatinine
measurements 48 to 72 hours after contrast exposure and
the resulting incidence rates of CI-AKI ranged from 0–11%,
depending on the definition used [21, 22]. Novel biomarkers
of acute kidney injury such as cystatin-C, IL-18, KIM-
1, and NGAL have been identified in recent years [23].
Further research is warranted to investigate whether these
novel biomarkers may have a role in improving the risk
stratification of patients receiving contrast material or in
refining the diagnostic criteria of AKI.
Ultimately, all of these are arbitrary definitions of CI-AKI
based on laboratory parameters. They are useful to create
a numerical measure that can be statistically compared in
clinical trials but bear no meaning for an individual patient.
Only hard outcomes such as dialysis or death from renal
failure are of real clinical significance.
Apart from these differences in the cutoff values defining
AKI, differences in terminology merit consideration. Until
a few years ago, any acute kidney injury occurring after
administration to iodinated contrast material and not other-
wise explained was assumed to be caused by contrast expo-
sure and hence referred to as contrast-induced nephropathy
(CIN) or contrast-induced acute kidney injury (CI-AKI) [2].
Considering the high rate of fluctuation in kidney function
in patients without exposure to iodinated contrast material
[7, 8], this terminology now appears greatly misleading,
unless strictly reserved for the attributable excess rate of AKI
caused by iodinated CM compared to a nonexposed control
group. Considering that it is impossible to determine on
an individual basis whether a decline in renal function was
caused by CM, other predisposing factors, or a combination
thereof, the term should be avoided in clinical practice when
referring to individual patients.The terms “postcontrast AKI”
or “postcontrast nephropathy” should be preferred since they
do not infer a causal relationship. Furthermore, catheteriza-
tion predisposes for renal compromise through mechanisms
unrelated to contrast materials which are discussed in more
detail below.Therefore, the terms “postcatheter nephropathy”
or “catheter-induced nephropathy” should be used instead of
“contrast-induced nephropathy” in patients after catheteriza-
tion.
3. Epidemiology
3.1. Incidence of AKI in the Absence of CM Exposure. As
discussed above, the epidemiology of CI-AKI has to be
seen in the context of the background rate of fluctuations
in kidney function and AKI observed in the absence of
contrast exposure. Such fluctuations are particularly frequent
in patients with chronic renal impairment andmore frequent
in hospitalized patients compared to outpatients due to a
higher rate of comorbidities predisposing to AKI [7, 8]. In
their meta-analysis of controlled studies of intravenous CM,
McDonald et al. [9] report an overall AKI rate of 6.5% in
the noncontrast CT group averaged over varying definitions
of AKI. Davenport et al. found AKI incidence rates in
the noncontrast group of 8.6% and 12.4% based on the
AKIN and more traditional CIN criteria, respectively [17].
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Using an absolute increase of serum creatinine 0.5mg/dL
from baseline to define AKI, McDonald et al. [10] found
AKI rates in the noncontrast control group of 4, 9, and 13
percent for patients with a baseline creatinine of <1.5, 1.5–2,
and ≥2mg/dL, respectively. These background rates of AKI
need to be taken into account when assessing whether CM
exposure increases the frequency of AKI.
3.2. Incidence of AKI following Intra-Arterial Administration
of CM. For a variety of reasons, the incidence of AKI is
substantially higher following coronary angiographic pro-
cedures than following contrast-enhanced CT [22]. The
patient population undergoing coronary procedures typically
has more advanced vascular disease and a higher rate of
hemodynamic compromise and is thus more predisposed
for AKI than the average population undergoing contrast-
enhanced CT [22, 24]. A larger volume of CM is typically
applied in cardiac angiography, particularly if an intervention
is performed during the procedure [22]. The site of CM
injection (intra-arterial versus intravenous) may also have a
direct influence possibly due to a higher initial concentration
ofCM in the renal vasculature, since it has been demonstrated
for aortography that the risk of AKI is greater if the CM
is injected immediately proximal to the renal arteries [4,
25]. Other authors, however, have challenged the notion
of an increased AKI risk from intra-arterial compared to
intravenous contrast administration [26, 27].
Furthermore, coronary angiography harbors a variety
of iatrogenic risk factors for AKI, which may increase the
risk of postcontrast AKI and are unrelated to the CM itself.
It is well known that cholesterol emboli and microemboli
from scraping of aortic plaque occur in a high percent-
age of patients during invasive angiographic procedures
[28]. Iatrogenic (micro-) embolization of renal parenchyma
may contribute to AKI following angiographic procedures
[4]. Other potential complications of coronary angiography
including arrhythmias, hemorrhage, myocardial infarction,
or aortic dissection can all lead to hypotension or reduced
cardiac output and thus contribute to postprocedural AKI
which may be falsely attributed to the CM [8].
These factors need to be consideredwhen interpreting the
incidence rates of AKI after coronary angiography and related
procedures. Reported incidence rates vary greatly depending
on the patient population, the nature of the procedure, and
definition of AKI. Postcontrast AKI is generally estimated
to occur in approximately 5–15% of patients after PCI [29].
A decreased baseline renal function has consistently been
found to be a strong predictor of postcontrast AKI risk [29].
The risk of post-PCI AKI has been shown to be significantly
higher with high-osmolar CM compared to low-osmolar
CM, but the iso-osmolar CM iodixanol has had conflicting
results in further reducing risk even in vulnerable patients
[29, 30]. Several studies have found evidence of a dose-
dependent risk increasing with CM volume administered
during the procedure [29, 31, 32]. Certain comorbidities
(diabetes, proteinuria, hypertension, and dehydration) and
nephrotoxic comedications further increase the risk of AKI
following angiographic procedures [33, 34].
3.3. Incidence of AKI following Intravenous Administration
of CM. The strongest currently available evidence on the
incidence of CI-AKI following intravenous CM adminis-
tration consists in a meta-analysis of controlled studies [9]
and two additional large controlled studies [10, 17] which
were published simultaneously and not included in the meta-
analysis. The meta-analysis analyzed 13 controlled studies
including more than 25,000 patients and found a similar or
lower rate of AKI following contrast-enhanced CT compared
to noncontrast CT [9].This result was confirmed in subgroup
analyses of patients with and without diabetes and with and
without renal insufficiency. It was further independent ofAKI
definition and CM osmolality. The latter finding may not
apply to high-osmolality contrast medium, since all but one
study included in the meta-analysis used iso- and/or low-
osmolality contrast media.
It is, however, important to keep in mind that all con-
trolled studies included in the meta-analysis had a non-
randomized study design, which inevitably makes them
vulnerable to selection bias, since patients perceived to be
at risk for AKI are more likely to receive noncontrast CT
examinations [2]. In the two more recent controlled studies
on AKI after intravenous CM administration, sophisticated
statistical methods of propensity score adjustment were
used to neutralize differences in AKI risk factors between
the contrast-enhanced and the noncontrast CT group and
thus counteract the effects of selection bias. The results of
these two studies have been partly conflicting. McDonald
et al. found that after propensity matching there was no
significant difference in AKI incidence between both groups
[10]. Subgroup analysis was performed for patients with a
baseline serum creatinine of <1.5, 1.5–2, and ≥2mg/dL, and
no significant difference between exposed and nonexposed
patients was found in either group. The second study by
Davenport et al. confirmed that there is no increased risk
for patients with a baseline serum creatinine of <1.5mg/dL
[17]. This study, however, found a significantly increased risk
for AKI after intravenous CM for patients with a baseline
serum creatinine of >1.5mg/dL, which further increased with
higher baseline creatinine levels [17]. In a separate analysis
of the same database, Davenport and colleagues analyzed the
rates of AKI between patients undergoing contrast-enhanced
and noncontrast CT using a risk group stratification based
on eGFR instead of serum creatinine [15]. In this analysis,
a significantly increased risk for the contrast exposed group
was found in patients with an eGFR of <30mL/min/1.73m2
(OR 2.78, 𝑃 = 0.02) and there was a trend of an increased risk
in patients with an eGFR of 30–44mL/min/1.73m2 (OR 1.41,
𝑃 = 0.07) [15].
How to explain and reconcile these conflicting results in
patients with preexisting renal impairment is a subject of
ongoing debate and has been discussed in detail elsewhere
[2]. Reasons of this apparent discrepancy may include dif-
ferences in patient population, contrast agent type, as well as
differences in patient referral and nephropathy prophylaxis
patterns [2]. Finally, propensity scoring can minimize the
effect of selection bias but may not completely eliminate
it, since the factors that prompted physicians to avoid a
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contrast-enhanced CT scan in individual patients may be
more numerous and subtle than a retrospective analysis can
account for. The ratio between contrast material dose and
creatinine clearance has been suggested as a predictor of
AKI risk from intravenous CM [35]. In hospitalized cancer
patients, recent chemotherapy, hypertension, and treatment
with bevacizumab have been identified as additional risk
factors [36].
The best method to avoid selection bias would be to per-
form a randomized controlled trial randomizing patients to
receiving noncontrast or contrast-enhanced CT. Such a trial
has not been performed and will likely never be performed,
since it appears unethical to randomize patients rather than
use clinical judgment to carefully balance the potential
diagnostic benefits and the risks of contrast administration
(not limited to AKI) for the specific clinical indication and
the risk factors of every individual patient.
Therefore, the true risk of CI-AKI from intravenous
administration of CM is not and may never be precisely
known. However, recently published evidence strongly sug-
gests that the risk caused by CM is much smaller than
previously thought based on noncontrolled studies. For
patients with a baseline creatinine of <1.5mg/dL and an
eGFR of ≥45mL/min/1.73m2 the risk of CI-AKI is likely
to be nonexistent. There is conflicting evidence for patients
with impaired renal function; an increased risk of AKI from
intravenous CMmay exist in this patient population.
4. Outcome
Although self-limiting in most cases, postcontrast AKI car-
ries a risk of more permanent renal insufficiency, dialysis,
and death [29]. Levy and colleagues retrospectively compared
the outcomes of 174 patients who developed AKI after CM
administration for various procedures with matched controls
who received CM but did not develop AKI [37]. This study
found a significantly increased risk of in-hospital mortality
(34% versus 7%) for those patients who developed post-AKI.
However, it has been pointed out that AKI in most of these
patients was probably not due to contrast material but other
comorbid and iatrogenic risk factors [5, 38].
Most available evidence on the outcome of postcontrast
AKI relates to intra-arterial CM administration for cardiac
catheterization or other angiographic procedures. In a retro-
spective study of patients with preexisting renal insufficiency
undergoing percutaneous coronary interventions (PCIs),
Gruberg and colleagues found a significantly increased risk
of in-hospital mortality (15% versus 5%) for those patients
who had a≥25% increase in serum creatininewithin 48 hours
following coronary procedures compared to those who did
not [42]. A similarly striking increase in in-hospital mortality
(21-22 versus 1–1.4%) in patients developing postcontrast AKI
after PCI has been found in other studies [39, 40]. The
incidence of AKI requiring dialysis after PCI is <1% in most
published cohorts [29, 32, 39, 41]. In this small subgroup of
patients, however, an even higher in-hospital mortality of 23–
36% has been demonstrated [32, 39, 41, 42].
An adverse prognostic value of postcontrast AKI has
also been demonstrated for longer-term mortality [38]. In
patients without preexisting chronic kidney disease, 1 year
cumulative mortality has been shown to be 8% and 3% in
patients who did and did not develop postcontrast AKI after
percutaneous coronary interventions, respectively [43]. In
patients with preexisting renal disease, 1 year cumulative
mortality increased from7% to 23% if patients developedAKI
after PCI. Similar results for the adverse effect of postcontrast
AKI on 1 year mortality have been found in other study
cohorts [39, 42]. One year mortality rates as high as 55%
have been reported in patients who developed AKI requiring
dialysis after PCI [41].
In summary, the literature has consistently demonstrated
that patients who develop postcontrast AKI after catheteri-
zation procedures have a significantly higher risk of dying
during the hospital stay and the next year. However, this
finding must be interpreted with caution since it is derived
from observational studies in which most postcontrast AKI
patients had comorbidities that not only increase their risk
of developing postcontrast AKI but also directly increase
mortality. The association between postcontrast AKI and
mortality, therefore, does not prove a causal relationship [38].
In contrast to intra-arterial CM for cardiac catheteriza-
tion or other angiographic procedures, the risk of adverse
outcome from postcontrast AKI is likely lower for intra-
venously administered CM. In an analysis of six prospective
studies including >1,000 total patients undergoing contrast-
enhanced CT with an overall postcontrast AKI rate of
5.1%, there was no case of dialysis or death resulting from
postcontrast AKI [5].
5. Conclusions
In conclusion, the risk of AKI from CM, in particular
when administered intravenously for contrast-enhanced CT,
has been exaggerated by older, noncontrolled studies. More
recent evidence from controlled studies suggests that the risk
is likely nonexistent in patients with normal renal function,
but there may be a risk in patients with renal insufficiency.
However, even in this patient population, the risk of CI-
AKI is probably much smaller than traditionally assumed.
Since volume expansion is the only preventive strategy with
a convincing evidence base [44], liberal hydration should
be encouraged to minimize the risk for all patients, both
with and without impaired renal function. Even though
there is conflicting data, we believe it is still prudent to be
more cautious in patients with significant renal impairment
(a baseline creatinine of >2.0mg/dL and/or an eGFR of
<30mL/min/1.73m2).The benefits of diagnostic information
gained from contrast-enhanced examinations will still need
to be balanced with the potential risk of CI-AKI for the
individual patient and clinical scenario.
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